S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells
Phase 3Completed 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Thalassemia Major
Conditions
Thalassemia Major
Trial Timeline
Dec 1, 2012 โ Dec 31, 2017
NCT ID
NCT01740531About S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells
S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells is a phase 3 stage product being developed by Cerus for Thalassemia Major. The current trial status is completed. This product is registered under clinical trial identifier NCT01740531. Target conditions include Thalassemia Major.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01740531 | Phase 3 | Completed |
Competing Products
20 competing products in Thalassemia Major
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Luspatercept | Merck | Phase 2 | 52 |
| luspatercept | Merck | Phase 2 | 52 |
| ACE-536 | Merck | Phase 2 | 52 |
| luspatercept | Merck | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Blood sample | Novartis | Pre-clinical | 23 |
| deferasirox + placebo | Novartis | Phase 2 | 52 |
| Zoledronic acid + Placebo | Novartis | Phase 2/3 | 65 |
| deferasirox | Novartis | Approved | 85 |
| deferasirox | Novartis | Phase 3 | 77 |
| ICL670 + deferoxamine | Novartis | Phase 3 | 77 |
| ruxolitinib | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 1 | 33 |
| Deferasirox | Novartis | Phase 3 | 77 |
Other Products from Cerus
Traditional Cryoprecipitate + Pathogen-Reduced CryoprecipitateApproved
77
Pathogen-Reduced Plasma + Crystalloid SolutionsApproved
77
S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - ControlPhase 3
69
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets. + Autologous apheresis Conventional untreated Platelet ComponentsPhase 2
44
INTERCEPT treated plateletsPhase 2
44